{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-Resistant+Prostate+Cancer&page=2",
    "query": {
      "condition": "Hormone-Resistant Prostate Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-Resistant+Prostate+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:00:58.395Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01267266",
      "title": "Saracatinib in Treating Patients With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "saracatinib",
          "type": "DRUG"
        },
        {
          "name": "hydrocortisone/placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 31,
      "start_date": "2010-12",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-01",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 15,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01267266"
    },
    {
      "nct_id": "NCT05551117",
      "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Androgen-Independent Prostatic Cancer",
        "Androgen-Insensitive Prostatic Cancer",
        "Androgen-Resistant Prostatic Cancer",
        "Hormone Refractory Prostatic Cancer",
        "Anal Cancer",
        "Anal Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Oral Squamous Cell Carcinoma",
        "Malignant Melanoma",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "vobramitamab duocarmazine 2.0 mg (Arm A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine 2.7 mg (Arm B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2023-06-13",
      "completion_date": "2025-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 14,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05551117"
    },
    {
      "nct_id": "NCT07288359",
      "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer",
        "Advanced CCNE1-amplified Solid Tumors",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GVV858",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2025-12-29",
      "completion_date": "2031-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288359"
    },
    {
      "nct_id": "NCT00570700",
      "title": "Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-refractory Prostate Cancer",
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Prostate Cancer",
        "Recurrent Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2007-07",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Loma Linda, California • Orange, California + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570700"
    },
    {
      "nct_id": "NCT00936975",
      "title": "Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Malignant Neoplasm in the Bone",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Fluorine F 18 Sodium Fluoride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2009-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-07-16",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936975"
    },
    {
      "nct_id": "NCT01270880",
      "title": "Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Hsp90 inhibitor STA-9090",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "enzyme-linked immunosorbent assay",
          "type": "OTHER"
        },
        {
          "name": "RNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "spectrophotometry",
          "type": "OTHER"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2011-01",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Piscataway",
          "state": "New Jersey"
        },
        {
          "city": "Wisconsin Rapids",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270880"
    },
    {
      "nct_id": "NCT01498978",
      "title": "Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2012-02-06",
      "completion_date": "2019-01-19",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • Portland, Oregon",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498978"
    },
    {
      "nct_id": "NCT07005154",
      "title": "A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic Castration-Resistant Prostate Cancer",
        "Metastatic Hormone Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ASP5541",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Adrenocorticotropic hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 218,
      "start_date": "2025-06-19",
      "completion_date": "2032-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 10,
      "location_summary": "Huntsville, Alabama • Tampa, Florida • Chicago Ridge, Illinois + 7 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago Ridge",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07005154"
    },
    {
      "nct_id": "NCT00132756",
      "title": "Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Doxil and Estramustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Morton Plant Mease Health Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2003-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-11-08",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 1,
      "location_summary": "Clearwater, Florida",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132756"
    },
    {
      "nct_id": "NCT01828476",
      "title": "Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "ABT-263",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2013-06",
      "completion_date": "2016-03-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-04",
      "last_synced_at": "2026-05-22T04:00:58.395Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828476"
    }
  ]
}